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AFP-producing acinar cell carcinoma treated by 
pancreaticoduodenectomy in a patient with a previous radical 
subtotal gastrectomy by gastric cancer
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We report a case of alpha-fetoprotein (AFP)-producing acinar cell carcinoma (ACC) of the pancreas. The tumor was 
diagnosed in a 72 yearold female after radical subtotal gastrectomy (Billroth I) due to early gastric cancer six months 
before. The initial serum AFP levels were increased to 2,254.1 IU/ml and preoperative imaging studies showed a mass 
with approximately 2.5 cm in diameter near the neck of the pancreas. A pancreaticoduodenectomy was performed. 
The pathologic examination revealed an ill-defined lobulating tumor confined to the pancreas (T1 stage). Immunohisto-
chemical study showed that the tumor cells expressed AFP. The Adenosine triphosphate-based chemotherapy re-
sponse assay (ATP-CRA) suggested that cisplatin would be more desirable than gemcitabine in AFP-producing ACC 
of the pancreas as an adjuvant chemotherapy. However, the adjuvant chemotherapy was not performed due to the 
early pathological stage. The patient died from carcinomatosis and pneumonia. Even if the tumor was on a relatively 
early stage, an adjuvant treatment should be considered ACC. (Korean J Hepatobiliary Pancreat Surg 2014;18:33-37)
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INTRODUCTION
The acinar cell carcinoma (ACC) is compared with the 
ductal cell carcinoma a rare pancreas tumor.1 ACCs ac-
count for less than 1% of primary pancreatic neoplasms.2 
In particular ,the pancreatic ACC associated with an ele-
vated serum alpha-fetoprotein (AFP) is extremely rare.3 
AFP is a glycoprotein with a frequently increase in pa-
tients with hepatocellular carcinoma and yolk-sac tumors.4 
It is not widely known that AFP production can accom-
pany pancreatic ACC.5 A standard chemotherapy regimen 
for AFP-producing ACC has not been established yet.6 In 
this report, a case of resected AFP-producing ACC of the 
pancreas is presented in a patient who underwent a radical 
subtotal gastrectomy due to an early gastric cancer. Also 
it is presented a potential chemotherapeutic regimen based 
on an in vitro adenosine triphosphate-based chemotherapy 
response assay (ATP-CRA).
CASE
A 72-year-old female patient was admitted to our hos-
pital for the evaluation and proper management of a pan-
creatic mass. Six months ago, she underwent a radical 
subtotal gastrectomy with gastroduodenostomy (Billroth I) 
due to early gastric cancer. This pancreatic mass was in-
cidentally identified on a postoperative follow-up abdomi-
nal-pelvic computed tomography (CT) scan. Her body 
weight was 39 kg and the height was 144 cm (body mass 
index, 18.8). A physical examination finding was an upper 
midline abdominal skin incision in the abdomen, which 
was soft and flat without palpable mass. All routine blood 
laboratory tests including amylase and lipase were within 
normal ranges. Also tumor markers, carcinoembryonic an-
tigen (CEA), carbohydrate antigen 19-9 (CA 19-9) and 
carbohydrate antigen 125 (CA 125) were within normal 
limits. In the CT scan, an approximately 2.5 cm-sized 
34  Korean J Hepatobiliary Pancreat Surg Vol. 18, No. 1, February 2014
Fig. 2. Intraoperative findings. Severe adhesions were noted, especially around the common hepatic artery and the celiac axis.
The pancreatic neck portion needed first to be dissected for the anatomic landmark identification. The round mass at the posterior
aspect of the pancreatic neck portion (long, thick arrow) should be noted (A), an operative finding after pancreatoduodenectomy.
The stump of the gastroduodenal artery is noted (short, thin arrow) (B). SMV, superior mesenteric vein; SV, splenic vein; PV,
portal vein; S, remnant stomach; P, remnant pancreas; BD, common hepatic duct.
Fig. 1. Preoperative image study findings. CT scan showed about a 2.5 cm-sized mass near the pancreatic neck portion without
evidences of distant metastasis (A). No definitive hypermetabolic signal intensity was shown in FDG-PET scan (B). Filling defect
and dilatation of the distal pancreatic duct was shown on magnetic resonance cholangiopancreatography (C).
mass near the neck of the pancreas with distal duct dilata-
tion and a parenchyma atrophic change abutting to the 
portal vein was identified. No lymph node enlargement or 
distant metastasis was detected (Fig. 1A).The 2-deoxy-2- 
[18F]-fluoro-D-glucose (FDG) positron emission tomog-
raphy (PET) showed approximately 2.6 cm-sized low-at-
tenuating pancreatic mass in the body portion without sig-
nificantly increased FDG uptake in any other organs (Fig. 
1B). Pancreaticobiliary magnetic resonance imaging with 
cholangiography showed about 2.5 cm-sized hypervascular, 
T2 low signal, fat-containing, well-defined mass in the 
neck area with distal parenchymal atrophy and duct dilata-
tion (Fig. 1C). The characteristics of the tumor seemed to 
be somewhat different from usual ductal adenocarcinoma 
of the pancreas, and serum AFP was checked. It was ele-
vated to 2,254.1 IU/ml (reference range: 0-7.0 IU/ml).
The patient underwent a pancreaticoduodenectomy (PD). 
During the laparotomy, malignant ascites, peritoneal seed-
ing or distant metastasis were not found, but severe peri-
toneal adhesions due to the previous radical subtotal gas-
trectomy were noted. The anatomic plane was obscured 
during the PD due to the previous lymph node dissection 
around the celiac axis, common hepatic artery and the 
proper hepatic artery. Therefore, a dissection between the 
neck of the pancreas and superior mesenteric vein-splenic 
vein-portal vein confluence was needed to identify the 
anatomic landmark (Fig. 2A). As previous lymph node 
dissection around major vessels was conducted already, a 
standard lymph node dissection was performed (Fig. 2B). 
Due to the previous gastroduodenostomy the reconstruction 
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Fig. 3. Surgical pathology and postoperative course. An about 1.9 cm- sized pancreas-confining lobulated tumor was noted on
the neck of the pancreas (A). The tumor cells are arranged in irregular solid sheets and acinar pattern (B, ×100), The AFP 
immunohistochemical staining was diffuse positive in tumor cells (C, ×100). The patient got no adjuvant chemotherapy in follow
up. The serial follow up of serum AFP showed re-elevation after declining near the normal level following operation (D). H&E, 
hematoxylin-eosin.
of gastrointestinal continuity was easy following the PD. 
All procedures, pancreaiticojejunostomy, hepaticojejuno-
stomy and gastrojejunostomy were completed in a usual 
manner.
An 1.9×1.7 cm-sized ill-defined lobulating tumor con-
fined to the pancreas was revealed in the macroscopic 
specimen examination (Fig. 3A). An AFP-producing ACC 
of the pancreas (T1 stage) was classified based on the rou-
tine hematoxylin and eosin (H&E) staining and im-
munohistochemical staining (Fig. 3B and 3C).
The postoperative recovery course was uneventful. The 
patient discharged 12 days postoperatively. For the poten-
tial possibility of application of chemotherapeutic agents 
in this rare case of pancreatic cancer, an ATP-CRA che-
mosensitivity test to anticancer drugs was performed 
(Table 1). The result showed cisplatin would potentially 
be more applicable than gemcitabine which is usually 
used in pancreatic cancer. Although the serum level of 
AFP had been dropped into normal range immediately af-
ter PD, it was rebounded exponentially 17 month post-
operative (Fig. 3D). The patient died due to carcinoma-
tosis and pneumonia at 30 months after the surgery.
DISCUSSION
Benassai et al.7 reported that AFP was elevated in only 
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Table 1. APT-CRA chemosensitivity report (Tumor inhibition 
rates at serial concentrations of TDC)
Drug
Concentration (xTDC) Index 
(Rank†)0.2x 1x 5x
Cyclophosphamide
Cisplatin
Oxaliplatin
5-Fluorouracil
Doxorubicin
Gemcitabine
Paclitaxel
Etoposide
 9.6
 0
20.7*
30.3*
26*
24.1*
 0
 2.9
31.3*
44.5*
32.8*
37.8*
26.9*
31.2*
10.6
32.3*
89.1*
84.2*
73.9*
58.9*
70.8*
50.2*
94.8*
69.6*
170 (1)
171.3 (2)
172.6 (3)
173 (4)
176.3 (5)
194.5 (6)
194.6 (7)
195.2 (8)
TDC, test drug concentration
*p＜0.05
Index=300-sum (of tumor inhibition rate 0.2x, 1x and 5x) 
†Rank=more desirable in drug tested
6% of ACC patients. Lee et al.8 reported that AFP was 
elevated in only 1 out of 29 Korean ACC patients. 
Kawamoto et al.9 reported that liver metastases were iden-
tified in 21 of the 28 patients with AFP-producing pancre-
atic cancer (76% overall). In the most of the reported cas-
es, the AFP-producing ACCs were found to be very ag-
gressive and required systemic chemotherapy. In the re-
ported case, the AFP-producing ACC presented this ag-
gressive nature of malignant characteristics. During the 
radical subtotal gastrectomy, no pancreatic lesion was 
found: the tumor needed only 6 month to become a 2.5 
cm-sized mass. In this case, resection could be conducted 
and T1 stage was reported due to the early tumor de-
tection during regular CT scans as follow up after the pre-
vious surgery. Therefore an early detection of pancreatic 
cancers could be suggested due to certain regular screen-
ing strategies.
Due to the previous radical subtotal gastrectomy, sev-
eral issues had to be considered before PD performance 
in the reported case. First, severe peritoneal adhesions 
were present, where dexterous skills are needed to expose 
the retroperitoneal organs adequately. In particular, the 
previous lymph nodes dissection around the celiac axis, 
the common hepatic artery and the proper hepatic artery 
resulted in a dense fibrous adhesion between the pancreas 
and the subhepatic area. The extensive dissection around 
these vessels lead to a potential vascular damage related 
to severe postoperative morbidity because the soft tissues 
around the major vessels had been removed in previous 
radical gastrectomy already. Therefore, a standard PD 
would be an appropriate surgical extent in patients who 
previously had radical gastrectomy. Last, the gastro-
intestinal anastomosis after PD is affected by the previous 
gastrointestinal anastomosis. In the present case, the pre-
vious gastroduodenostomy made this reconstruction easy. 
But in the case of a previous gastrojejunostomy, a differ-
ent reconstruction strategy needs to be considered.
Gemcitabine is a first-line cancer drug widely used for 
the chemotherapy in the ductal adenocarcinoma.10 However, 
a chemotherapy regimen for AFP-producing ACC has not 
been established yet because the number of affected pa-
tients is too small.6 An in-vitro ATP-CRA (Table 1) was 
performed by us to evaluate the chemosensitivity of anti-
cancer drugs for the potential application of chemo-
therapeutic agents in this rare pancreatic cancer case. In 
recent studies it was found that ATP-CRA results can pre-
dict the chemosensitivity in patients with ovarian cancer, 
gastrointestinal cancer or breast cancer.11-13 Our result 
showed cyclophosphamide is the most desirable drug 
which was tested for AFP-producing ACC of the pancreas 
followed by cisplation and gemcitabine is less effective 
than cyclophosphamide or cisplatin for the AFP-producing 
ACCs. According to our institutional experience,14 ACCs 
are very rare and show aggressive biologic behaviors such 
as regional or distant metastasis at the initial time of 
diagnosis. Currently the best treatment approach is the cu-
rative resection according to our institutional experience.14 
The reported patient received no postoperative adjuvant 
chemotherapy after the curative pancreatectomy because 
the tumor was reported as an early pancreatic cancer 
(T1N0M0, Stage I). However, the patient experienced ag-
gressive carcinomatosis recurrence, cachexia and pulmo-
nary complications, and deteriorated rapidly without appli-
cation time for adjuvant or palliative chemotherapy. Based 
on the ATP-CRA, it might have been beneficial to apply 
adjuvant chemotherapy even if the tumor was on a rela-
tive early stage. To determine an effective chemotherapy 
regimen for AFP-producing ACCs, further experience and 
studies are necessary.
In summary, the AFP-producing ACC is a very rare 
malignant pathology in pancreas which requires curative 
pancreatectomy. Complex difficulties in the PD occurred 
due to the previous radical subtotal gastrectomy and the 
surgeon in particular needed to consider the anatomic 
relationships. Adjuvant postoperative chemotherapy based 
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on the results of ATP-CRA test should be considered in 
this rare and unusual malignancy as well. 
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